clinicaltrials.gov
ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days RSS plūsma
Saņem jaunākos atjauninājumus no ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days uzreiz, tiklīdz tie parādās.
Jaunākie ieraksti
Lasiet ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days tur, kur parasti lasāt
Cilvēki, kuri seko ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days, seko arī
-
Chugai Pharmaceutical: News Releases chugai-pharm.co.jp
-
Bristol Myers Squibb Press Releases news.bms.com
-
Regeneron Pharmaceuticals Inc. News Releases investor.regeneron.com
-
What's new ema.europa.eu
Jautājumi
Kāda ir ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days RSS plūsmas URL adrese?
Plūsmas adrese ir https://clinicaltrials.gov/ct2/results/rss.xml?rcv_d=&lup_d=14&sel_rss=mod14&term=mezagitamab+%28TAK+079%29&recrs=abdf&type=Intr&phase=0124&fund=2&count=10000. Ielīmējiet to jebkurā RSS lasītājā vai noklikšķiniet uz Sekot tagad, lai lasītu to Feeder.
Cik bieži ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days publicē ierakstus?
ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days publicē ierakstus retāk nekā reizi nedēļā. Pēdējais ieraksts tika publicēts pirms 12 dienas.
Vai ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days RSS plūsma darbojas?
Jā. Feeder to pārbaudīja pirms apmēram 1 stunda, un plūsma atbildēja kā parasti.
Kā sekot ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days pakalpojumā Feeder?
Noklikšķiniet uz Sekot tagad un reģistrējieties, ja jums vēl nav konta. Feeder bezmaksas plāns ietver līdz 200 plūsmām tīmeklī, iPhone un Android ierīcēs. Kredītkarte nav nepieciešama.
Sekojiet ClinicalTrials.gov: mezagitamab (TAK 079) | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | Interventional Studies | Phase Early Phase 1, 1, 2, 3 | Industry | Last update posted in the last 14 days pakalpojumā Feeder
Feeder bezmaksas plāns ietver līdz 200 plūsmām tīmeklī, iPhone un Android ierīcēs. Kredītkarte nav nepieciešama.